Showing 1188 results
- Media Release /68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from…
- Media Release /Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap…
- Media Release /Six African nations will join a partnership pioneered in Ghana using technology to track and better tackle sickle cell disease (SCD) Includes expanded rollout of an app to track babies diagnosed…
- Media Release /Kisqali is the only CDK4/6 inhibitor with consistent overall survival (OS) benefit seen across all three Phase III trials, with the longest median OS benefit ever reported for HR+/HER2- mBC1-10 OS…
- Media Release /Biomarker analysis from Phase III SOLAR-1 study shows Piqray plus fulvestrant had clinical benefit regardless of presence of ESR1 mutations and genes implicated in CDK4/6i resistance1 Piqray plus…
- Media Release /Kymriah offers patients in Europe with advanced follicular lymphoma a potentially definitive, single infusion CAR-T cell therapy with a remarkable safety profile Approval based on the Phase II…
- Media Release /With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for…
- Media Release /Jakavi is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GvHD)1,2 In clinical…
- Media Release /Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New JerseyThis action has been taken out of an abundance of…
- Media Release /Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 119
- › Next page